Information

• 2022
• 2021
• 2020

2022

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

2021

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

2020

• December 3, 2020

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY

• October 28, 2020

  INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB

• February 14, 2020

  EISAI TO VOLUNTARILY WITHDRAW ANTIOBESITY AGENT BELVIQ® / BELVIQ XR® IN THE U.S.